NRAS hypermutability in familial melanoma with CDKN2A mutations - Cause and effect?

Journal of the National Cancer Institute

Volumn 95, Issue 11, 2003, Pages 768-769

  Kraemer, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ARGININE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSINE; GLUTAMINE; LYSINE; PROTEIN P14; PROTEIN P16; PROTEIN P53; PYRIMIDINE DERIVATIVE; RETINOBLASTOMA PROTEIN; THYMINE; UNCLASSIFIED DRUG;

CELL CYCLE; CHROMOSOME 9P; DNA DAMAGE; DNA SEQUENCE; EDITORIAL; FAMILIAL CANCER; GENE INACTIVATION; HUMAN; LASER MICROSCOPY; LIGHT EXPOSURE; LYMPHOBLASTOID CELL LINE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE N RAS; PRIORITY JOURNAL; SKIN CANCER; SOMATIC HYPERMUTATION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; XERODERMA PIGMENTOSUM; GENETIC MARKER; GENETICS; MUTATION; NOTE; ONCOGENE RAS; RADIATION EXPOSURE; SKIN TUMOR; SUNLIGHT;

GENES, P16; GENES, RAS; GENETIC MARKERS; GERM-LINE MUTATION; HUMANS; MELANOMA; MUTATION; SKIN NEOPLASMS; SUNLIGHT; ULTRAVIOLET RAYS;

EID: 0038718589     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.11.768     Document Type: Editorial

References (19)

1. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
2. Milligan A, Gabrielli BG, Clark JM, Hayward NK, Ellem KA. Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res 1998;422:43-53.
3. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003:95:790-8.
4. Brash DE, Seetharam S, Kraemer KH, Seidman MM, Bredberg A. Photo-product frequency is not the major determinant of UV base substitution hot spots or cold spots in human cells. Proc Natl Acad Sci U S A 1987:84: 3782-6.
5. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003;21:217-28.
6. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996;1:136-42.
7. van der Lubbe JL, Rosdorff HJ, Bos JL, van der Eb AJ. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res 1988;3:9-20.
8. Bootsma D, Kraemer KH, Cleaver JE, Hoeijmakers JH. Chapter 14. Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York (NY): McGraw-Hill; 2002. p. 211-37.
9. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994;130:1018-21.
10. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987;123:241-50.
11. Waters HL, Seetharam S, Seidman MM, Kraemer KH. Ultraviolet hypermutability of a shuttle vector propagated in xeroderma pigmentosum variant cells. J Invest Dermatol 1993;101:744-8.
12. Perera MI, Um KI, Greene MH, Waters HL, Bredberg A, Kraemer KH. Hereditary dysplastic nevus syndrome: lymphoid cell ultraviolet hypermutability in association with increased melanoma susceptibility. Cancer Res 1986;46:1005-9.
13. Seetharam S, Waters HL, Seidman MM, Kraemer KH. Ultraviolet mutagenesis in a plasmid vector replicated in lymphoid cells from patient with the melanoma-prone disorder dysplastic nevus syndrome. Cancer Res 1989;49:5918-21.
14. Moriwaki SI, Tarone RE, Kraemer KH. A potential laboratory test for dysplastic nevus syndrome: ultraviolet hypermutability of a shuttle vector plasmid. J Invest Dermatol 1994;103:7-12.
15. Moriwaki SI, Tarone RE, Tucker MA, Goldstein AM, Kraemer KH. Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. Cancer Res 1997;57:4637-41.
16. Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 1999;285:263-5.
17. Yuasa M, Masutani C, Eki T, Hanaoka F. Genomic structure, chromosomal localization and identification of mutations in the xeroderma pigmentosum variant (XPV) gene. Oncogene 2000;19:4721-8.
18. Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ. DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2001;2:537-41.
19. Broughton BC, Cordonnier A, Kleijer WJ, Jaspers NG, Fawcett H, Raams A, et al. Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. Proc Natl Acad Sci U S A 2002;99: 815-20.